$WAT

WAT Upgraded by Piper Sandler -- Price Target Raised to $480

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.

Original reporting
Published Aug 27, 2026, 5:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 7:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$WAT
Bullish
medium confidence
Mentioned
$WAT
Relevance
7/10
alphai data visualization · based on gurufocus.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The upgrade reflects confidence in growth prospects post‑merger, but valuation concerns remain.

02

Market read

Analyst upgrade could trigger buying interest and modest price appreciation for WAT.

03

What to watch

Insider selling of $1.4 M and a modest GF Value gap suggest caution.

Relevance 7/10Novelty 7/10Timing: post‑upgrade

Background

Waters Corp provides analytical instruments for life‑science research; recent merger with Becton Dickinson expanded its diagnostics portfolio.

Company-level read

Ticker impact

$WATBullishMedium confidence
Context

Piper Sandler upgraded Waters Corporation to Overweight and raised the price target to $480.

Expected impact

Potential upside of 5‑10% as investors price in the higher target.

Evidence & confidence

Upgrade is a fresh, material event for a mid‑cap stock; however the valuation is already premium.

Market effects

May boost sentiment for the healthcare diagnostics and analytical instruments sector.

Limited to U.S. and global biotech/instrument markets.

Modest; primarily affects Waters and peers in life‑science tools.

Counterpoint

The stock appears overvalued with a high P/E; the upgrade may be premature.

Key entities

  • Waters Corporation

    Provider of chromatography and mass‑spectrometry tools.

  • Piper Sandler

    Equity research firm that issued the Overweight upgrade.

Related articles

$WATHighAI 8/10

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

$WATHighAI 9/10

Waters (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.

$WATMedAI 8/10

Waters Corporation Q2 2026 Earnings Call Summary

Waters Corp reported 9% organic constant-currency growth in Q2 2026, citing strength in pharma and academic end markets and a 400 bps growth acceleration in newly acquired Biosciences and Diagnostic Solutions. The company raised 2026 organic revenue guidance to 7-9%, expects acquired businesses to exit 2026 at 6%+ growth, and projects mid-teens adjusted EPS growth with margin expansion.